← News·MarketsMarkets

AIM ImmunoTech commits $1.5 million to Ampligen drug substance batches in Sterling Pharma pact

In focus: AIM ImmunoTech (NYSE American: AIM) and a July 31, 2026, Proposal Agreement with contract manufacturer Sterling Pharma Solutions that commits approximately $1.5 million over 12 months to produce fresh batches…

NM
NewsMV Markets Desk
3 min read
6 August 2026Markets desk
Share this dispatch
TickersAIM
Categoryregulatory

Filed via sec.gov

Keep reading

More from the markets desk